Goldfinch Bio, a U.S.-based, clinical stage biotechnology company focused on discovering and developing precision medicines for the treatment of kidney diseases, today announced it entered into a license agreement with Takeda Pharmaceutical Company Limited (“Takeda”) for worldwide rights to a preclinical, peripherally-restricted cannabinoid receptor 1 (CB1) monoclonal antibody.
Elicio Therapeutics, a next generation immuno-oncology company, announced today that it has closed its $33 million Series B financing.
Lantheus Holdings has signed an agreement to acquire oncology company Progenics Pharmaceuticals in an all-stock transaction.
Swedish Orphan Biovitrum (Sobi) has agreed to acquire Dova Pharmaceuticals in a deal valued at around $915m.
Blade Therapeutics, a biopharmaceutical company advancing novel anti-fibrotic therapies, today announced the acquisition of ATXCo, Inc., including its core asset, PAT-409, a Phase I ready autotaxin inhibitor for patients with fibrotic diseases.
Amphivena Therapeutics, Inc., a private clinical stage immuno-oncology company developing T cell engager therapeutics for cancer, announced today the closing of a $62 million Series C financing.
Pfizer has expanded its collaboration with oncology software provider Flatiron Health to integrate and increase the application of real-world data further in its development of targeted cancer drugs.
Boehringer Ingelheim has forged a co-development and license agreement worth $160m (£128.8m) with science-based company Inflammasome Therapeutics to develop up to three new therapies for retinal diseases.
Ironwood Pharmaceuticals, a GI healthcare company, announced today that it has amended its collaboration agreement with AstraZeneca for the development and commercialization of LINZESS in China.
Accenture has announced a collaboration with Bayer to implement the Accenture INTIENT Clinical platform to help simplify and speed its drug development processes.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.